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UTILITIES METHODOLOGY ISSUES
U'I'I
TRADE-OFF PREFERENCES FOR
PHARMACEUTICAL DEVELOPMENT,
MARKETING, AND OUTCOMES EVALUATION
Johnson FR, Desvousges WH
Triangle Economic Research, Durham, NC, USA
In this workshop the presenters discuss limitations of
standard QAL Y estimates for evaluating health-care
treatments and outcomes. As a solution, they demon-
strate developing, administering, analyzing, and applying
a recent stated-preference (SP) or conjoint-analysis health
survey. The authors are among a small group of heath
economists who recently have begun to employ this ap-
proach to elicit preferences for risk-benefit trade-offs,
public-health benefits of reduced pollution exposures,
benefits of increased longevity, and quality-of-life differ-
entials among various cardio-pulmonary symptoms. SP
encompasses a variety of multiattribute preference-elicita-
tion survey techniques widely used by market researchers
to evaluate potential new products and new markets for
existing products. The SP technique is based on the prin-
ciple that products are composed of various attributes or
features. SP allows respondents to systematically rate,
rank, or choose trade-offs among attributes using a frac-
tional-factorial experimental design. The attributes of
these health outcomes may include symptoms, daily ac-
tivities, number of episodes, and costs or adverse side ef-
fects associated with treatment alternatives. Respondents'
trade-offs among outcomes, treatments, or other health-
care options indicate the relative importance of various
attributes. The workshop will help participants to iden-
tify salient attributes for pharmacoeconomic decisions
and to construct appropriate experimental designs. Ad-
ministration of a computerized survey also will be dem-
onstrated. The presenters will show how responses elic-
ited from this survey are employed to develop a measure
of health-state preferences. Such survey results are useful
for a wide variety of pharmaceutical and health-outcome
applications, including pharmaceutical development
strategies, formulary decisions, managed-care insurance
coverage, new drug market share forecasting, patient-sat-
isfaction assessment, information dissemination and la-
beling evaluation, public health policy analysis, and cost-
effectiveness comparisons across diverse outcomes.
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PRACTICAL APPLICATIONS OF THE HEALTH
UTILITIES INDEX
Torrance GWI.2, Walker VI, Rosner AJ'
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The Health Utilities Index is designed to describe and to
quantify the health status and the health-related quality-
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of-life (HRQOL) of subjects. This validated and reliable
instrument has been employed by over 100 research
groups worldwide and exists in three formats (face-to-
face interview, telephone interview and self-administra-
tion). Translations into several languages are also avail-
able. As a generic preference-weighted system, the Health
Utilities Index not only measures and describes health
status, but also provides a quantitative measure of
HRQOL as a single summary score based on community
preferences for health status. The score, founded on util-
ity theory and anchored to the conventional 0-1 (dead-
healthy) scale, is appropriate as a quality-weight in the
calculation of quality-adjusted life-years (QALYs). Given
that QALYs have been recognized as a universal measure
for use in cost-effectiveness/cost-utility analyses and are
recommended in the reporting and monitoring of popula-
tion health, this instrument has wide ranging applications
in outcomes and health economic research. This work-
shop will provide an introduction to the Health Utilities
Index and focus on its practical application. We will de-
scribe our experiences as they relate to issues such as fre-
quency and mode of administration, patient recall, com-
pliance, sample size considerations, data analysis and
interpretation. Citing previous studies, this workshop
will demonstrate how the Health Utilities Index can be
utilized in prospective clinical research, patient surveys
and as a means for developing utility estimates in retro-
spective health economic models. Researchers and ana-
lysts involved in quality-of-life and health economic eval-
uations will gain a working knowledge of the Health
Utilities Index and an appreciation of its diversified use as
a generic HRQOL instrument.
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The measurement of health outcomes is central to all
evaluative studies. Clinical practice too is shaped by the
need to monitor health status, and changes in health sta-
tus. A prime requirement in most studies is the capacity
to represent benefits (or disbenefits) in terms of a single,
aggregate value. This property is typically absent from
profile measures that characterise health status in terms
of separate dimension scores. EQ-5D is a generic measure
that yields a single index value for health status based on
self-reported problems on each of 5 dimensions-mobility,
self care, usual activity, pain/discomfort, anxiety/depres-
sion. Utility weights for each of 245 health states are
available. EQ-5D is one of a handful of measures recom-
mended by the Washington Panel on Cost-Effectiveness.
Elsewhere EQ-5D has received official sanction under the
European Commission BIOMED programme and has
